Effect of Intravenous Ketamine Administration on Blood Glucose Levels in Conscious Rabbits

1Suleiman I. Sharif and 2Hanan A. Abouazra
1Department of Pharmacology, College of Pharmacy, University of Sharjah, UAE
2Department of Biology, Faculty of Science, University of Waterloo, 200 University Avenue West, Waterloo, Ontario, Canada N2L 3G1

Abstract: Problem statement: The intravenous general anaesthetic ketamine has been shown to produce changes in blood glucose levels. It is important to study the pharmacological basis of such an effect. Approach: The influence of varying doses of ketamine administered intravenously was studied in conscious rabbits. Serum glucose was determined by blood glucose method using an enzymatic PAP kit. Results: Low doses of ketamine (166.6 mg kg$^{-1}$) produced hyperglycaemia while higher doses (1 and 2 mg kg$^{-1}$) produced hypoglycaemia. However, at even a higher dose, ketamine (4 mg kg$^{-1}$) did not influence blood glucose levels. The dual effect of ketamine was resistant to $\alpha_1$-adrenoceptor blockade by WB-4101. On the other hand, the opioid antagonist naloxone blocked the hypoglycaemic and potentiated the hyperglycaemic effects of ketamine. Blockade of $\alpha_2$-adrenoceptors by yohimbine, abolished hyperglycaemia by ketamine and reversed its hypoglycaemic effect into hyperglycaemia that was sensitive to blockade by propranolol. Conclusion: Ketamine had a dual effect on blood glucose level. Its hyperglycaemic effect seemed to be mediated through $\alpha_2$-adrenoceptors while the hypoglycaemic effect is possibly mediated through opioid receptors with an involvement of $\beta$-adrenoceptors that only become evident after blockade of $\alpha_2$-adrenoceptors. Similar mechanisms may operate during ketamine anaesthesia. Plans were under preparations for future investigations on blood glucose levels of patients undergoing dental surgical procedures under ketamine anaesthesia, the results of which may prove clinically important.

Key words: Ketamine, conscious rabbits, blood glucose, intravenous

INTRODUCTION

Ketamine, a phencyclidine derivative, is widely used as a general Intravenous (i.v.) anaesthetic agent\cite{1}. Good analgesia and maintenance of many protective reflexes characterize the anaesthetic properties of ketamine\cite{1,2}. The properties of ketamine differ from other general anaesthetics (1) and have led ketamine along with phencyclidine and other related agents to be classified as dissociative anaesthetics\cite{3}. Both anaesthesia and surgery has been reported to affect blood glucose levels in humans\cite{4} ketamine anaesthesia appears to produce a significant elevation of blood glucose level in humans, during gynecological laparotomy\cite{5} and heart surgery\cite{6}. Furthermore, the same effect has been reported in rats\cite{7,8} and baboon\cite{9}.

Surgical procedures evoke an endocrine response and changes metabolism towards catabolism and it has been suggested that the endocrine response to anaesthesia is less than that to major surgical procedures\cite{10,11}. The same authors suggested that blood sugar rises during surgery to an extent depending much more on the degree of stress than the type of anaesthesia and the lighter the anaesthesia the greater the blood sugar response. Thus, it seems rather difficult to pinpoint with certainty the influence of the anaesthetics themselves among other variables such as the effects of the duration of the surgical operation\cite{12,13} and stress\cite{12} on blood glucose level. This study was designed to elucidate the effects of i.v. ketamine on blood glucose level in conscious rabbits and the possible mechanisms contributing to such effects.

MATERIALS AND METHODS

Animals: Healthy adult male New Zealand white rabbits, average age~3 months, weighing between 2.5-3.0 kg, bred in the animal house of the Al-Arab
Medical University, Benghazi, Libya, were used. Animals in all experiments were provided with a standard laboratory diet and had free access to tap water. The rooms in which they were housed were maintained at 22-23°C on a 12 h light/dark cycle. Al-Arab Medical University Animal Care and Use Committee approved all procedures carried out in this study.

Drugs: Drugs used in this study were ketamine HCl, Propranolol, yohimbine HCl (Sigma Chemical Co., St Louis, Mo, USA), naloxone HCl (Antigen, Roscrea, Ireland) and WB-4101 HCl ([2-(2, 6-dimethoxy phenoxy ethyl) amino ethyl-1, 4-benzodioxane] hydrochloride; Funakoshi, Tokyo, Japan) was obtained as powder. Saline (0.9% NaCl solution) was used as a vehicle for both naloxone and ketamine, while distilled water was used as a vehicle for yohimbine, propranolol and WB-4101.

Study protocol: Food was withdrawn 24 h before the start of each experiment. Control samples of blood were withdrawn at an interval of 30 min before the injection of a drug and the mean of these samples was taken as the control blood glucose level. Intravenous injections were made through the marginal ear vein and blood samples were collected in tubes, which were immediately centrifuged for 5 min at 3000 rpm to obtain serum. After collection, a digital pressure was applied to the collection site until bleeding has stopped and the ear was cleaned. If the rabbit was used for more than one experiment, an interval of at least seven days was allowed before the second experiment. Serum glucose level was determined by blood glucose oxidase method using Bio-Merieux enzymatic PAP_250 kits (Sigma Chemical Co., St Louis, Mo, USA). The color intensity was read on a Beckman spectrophotometer at 505 nm wave length. Al-arab Medical University Animal care and Use Committee approved all procedures performed in this study.

Statistical analysis: Results are expressed as mean±SEM of “n” observations, where “n” represents the number of animals used. Statistical analysis was performed using the One-Way Analysis Of Variance (ANOVA) to compare among the groups for overall differences. A paired Student’s t-test was used to compare between the test groups and control. A level of significance of p<0.05 was accepted.

RESULTS

Blood glucose level of unanaesthetized naive rabbits: In our experiments, New Zealand white rabbits that were apparently healthy and were not previously exposed to any drug treatment had an average fasting blood glucose level of 94.6±0.54 mmol L⁻¹ (n = 120) and ranged between 80.2-110.4. No significant changes were observed in response to i.v. administration of 1 ml of either saline or distilled water, so that they were used as vehicles for all drugs used in this study.

Effect of intravenously administered ketamine: As shown in (Fig. 1a), ketamine at total doses of 50 and 200 µg, (16.66 and 66.6 µg kg⁻¹, respectively) produced no significant changes in blood glucose level. However, a higher dose of ketamine, 500 µg, (166.6 µg kg⁻¹) produced hyperglycaemia that was only significant (p<0.01) at 15 and 30 min following it's administration. With further increases in the dose of ketamine to 1 and 2 mg kg⁻¹, a hypoglycaemic response was observed (Fig. 1b). The decrease in blood glucose level was maximum at 15 min for ketamine (1 mg kg⁻¹), but at 60 min for ketamine (2 mg kg⁻¹). Two hours later,

Table 1: Effect of i.v. ketamine given alone and in the presence of naloxone on blood glucose levels in conscious rabbits

<table>
<thead>
<tr>
<th>Drug regimen used</th>
<th>No. of Control</th>
<th></th>
<th>Minutes after drug injection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of animals</td>
<td>Control (0) min</td>
<td>5</td>
</tr>
<tr>
<td>Ketamine (500 µg)</td>
<td>5</td>
<td>93.4±3.10</td>
<td>106.0±0.2</td>
</tr>
<tr>
<td>Ketamine (4 mg Kg⁻¹)</td>
<td>5</td>
<td>94.8±1.20</td>
<td>96.4±2.4</td>
</tr>
<tr>
<td>Naloxone (0.25 mg Kg⁻¹)</td>
<td>5</td>
<td>95.5±2.60</td>
<td>96.9±6.4</td>
</tr>
<tr>
<td>Naloxone (1 mg Kg⁻¹)</td>
<td>5</td>
<td>93.5±0.80</td>
<td>101.0±1.2</td>
</tr>
<tr>
<td>Naloxone (0.25 mg Kg⁻¹)</td>
<td>6</td>
<td>96.0±2.20</td>
<td>98.0±2.8</td>
</tr>
<tr>
<td>Ketamine (500 µg)</td>
<td>5</td>
<td>118.7±1.20</td>
<td>120.0±4.1***</td>
</tr>
<tr>
<td>Naloxone (1 mg Kg⁻¹)</td>
<td>6</td>
<td>118.0±0.80</td>
<td>133.2±1.4***</td>
</tr>
<tr>
<td>Naloxone (1 mg Kg⁻¹)</td>
<td>6</td>
<td>118.0±0.80</td>
<td>133.2±1.4***</td>
</tr>
</tbody>
</table>

Fasted rabbits received either i.v. injection of the vehicle or naloxone. Control blood samples were withdrawn at 0, 15, 30 min (the mean was taken as 0 min control value), followed by either i.v. ketamine or naloxone depending on the regimen applied. Data are expressed as mean±SEM. Statistically significant differences are compared with ketamine not pre-treated with naloxone and represented as **: p<0.01; ***: p<0.005.

Blood glucose levels were not different from the pre-drug level for both doses. At a higher dose of ketamine (4 mg Kg⁻¹), no significant changes were observed in blood glucose level up to 1 h, but blood glucose level was significantly (p<0.05) raised at 2 h. However, at the high doses of ketamine (1-4 mg Kg⁻¹, i.v.) tested all rabbits exhibited excitation and teeth chattering that lasted for only 5 min.

**Effect of intravenous ketamine in the presence of naloxone:** As it can be shown in Table 1, naloxone (0.25 mg Kg⁻¹) produced no effect of its own and when given 30 min earlier, it did not affect the hyperglycaemia in response to ketamine (500 µg, i.v.). However, naloxone (1 mg Kg⁻¹, i.v.), a dose which usually produces hyperglycaemia, when it is given 30 min prior to ketamine (500 µg, i.v.), it significantly (p<0.005) potentiated the hyperglycaemic effect in response to ketamine at 5, 30 and 60 min. after ketamine injection. Interestingly, the highest dose of ketamine (4 mg Kg⁻¹, i.v.) tested that was without any effect on blood glucose levels, seems to potentiate the hyperglycaemic effect of naloxone (1 mg Kg⁻¹)-as in the presence of ketamine, naloxone produced much greater rise in blood glucose levels than that produced in the absence of ketamine. In experiments, to test the influence of naloxone (1 mg Kg⁻¹, i.v.) on hypoglycaemia-induced by ketamine (2 mg Kg⁻¹, i.v.), no changes were observed in blood glucose and the effects produced by each drug alone were lost (Fig. 2).

**Effect of intravenous ketamine in the presence of yohimbine:** Yohimbine (1 mg Kg⁻¹, i.v.) produced no significant changes in blood glucose levels, but when given 30 min prior to ketamine (500 µg, i.v.), it completely blocked the hyperglycaemic response to the later drug (Fig. 3). However, both yohimbine (1) and ketamine (4 mg Kg⁻¹, i.v.) were without any appreciable effect on blood glucose, whether each was administered alone or when both drugs were combined and no

Fig. 3: Blockade of ketamine-induced hyperglycaemia by yohimbine. Fasted rabbits received i.v. injection of the vehicle, C, followed 30 min later by i.v. ketamine, K, (500 µg), or i.v. yohimbine, Yoh, (1 mg kg⁻¹), followed 30 min later by i.v. ketamine, K, (500 µg). Each point represents mean of results from 6 rabbits. Vertical lines represent SEM. Asterisks indicate significant difference from control. **: p<0.01, ***: p<0.005. Student’s t-test

Fig. 4: Reversal of ketamine-induced hypoglycaemia by yohimbine. Fasted rabbits received i.v. injection of vehicle, C, followed 30 min later by i.v. ketamine, K, (2 mg kg⁻¹), or i.v. yohimbine, Yoh, (1 mg kg⁻¹), followed 30 min later by i.v. ketamine (2 mg kg⁻¹). Each point represents mean of results from 6 rabbits. Vertical lines represent SEM. Asterisks indicate significant difference from control, *: p<0.05, ***: p<0.005. Student’s t-test

Fig. 5: Effect of propranolol and WB-4101 on the reversal of ketamine-induced hypoglycaemia by yohimbine. In these experiments, two control blood samples were withdrawn at 0, 15 min and immediately propranolol or WB-4101 was given, followed 15 min later by yohimbine and at 60 min, ketamine was given. All injections were given i.v. to fasted rabbits. Each point represents mean of results from 6 rabbits. Vertical lines represent SEM. Asterisks indicate significant difference from control, *: p<0.01, ***: p<0.005. Student’s t-test

behavioral changes were observed with any of these treatment schedules. In the presence of yohimbine (1 mg kg⁻¹, i.v.), the hypoglycaemia in response to ketamine (2 mg kg⁻¹, i.v.) was reversed into a significant hyperglycaemia that persisted up to 2 h (Fig. 4)). Reversal of ketamine (2 mg kg⁻¹, i.v.)-induced hypoglycaemia by yohimbine (1 mg kg⁻¹, i.v.) was not influenced by pretreatment with the α₁-adrenoceptor antagonist WB-4101 (50 µg kg⁻¹, i.v.) given 15 min before yohimbine. However, in the presence of the non-selective β-adrenoceptor antagonist propranolol (1 mg kg⁻¹) yohimbine was without any effect on ketamine-induced hypoglycaemia (Fig. 5).

**DISCUSSION**

Ketamine anaesthesia appears to produce a significant elevation of blood glucose level during surgery. It has been suggested that the hyperglycaemic response to surgery was related to the duration of the surgical operation and the extent of its stress. Our preliminary results ascertained that the observed changes in blood glucose level are not a
consequence of stress as changes in response to i.v. ketamine are dose-dependent and can occur in either direction. In addition, at certain dosage level, ketamine did not alter control blood glucose levels. In our experiments, Ketamine at doses of 50 and 200 µg (16.66, 66.6 µg kg\(^{-1}\)) was without effect on blood glucose levels. Only on increasing the dose of i.v. ketamine to 500 µg (166.6 µg kg\(^{-1}\)), a significant rise in blood glucose was evident at 15 and 30 min following drug administration. This result recalls similar observations with ketamine in children\(^{[15]}\) and rats\(^{[16]}\) and ketamine-xylazine in rabbits\(^{[17]}\). Surprisingly, further increase in the dose of ketamine to (1 and 2 mg kg\(^{-1}\)) led to the precipitation of marked hypoglycaemia. Interestingly, at a higher dose tested, ketamine (4 mg kg\(^{-1}\)), was without effect and blood glucose level remained unchanged. This adds further support to the point that ketamine may have a dual effect on blood glucose level. In this context, it is interesting to mention that it has been previously suggested that ketamine, like cocaine, possesses the dual properties of neuronal noradrenaline uptake blockade and local anaesthetic-type depression of synaptic transmission, however, whereas cocaine possesses the former property at low doses and the latter at high doses, while for ketamine, the optimal doses for each property are rather close and, therefore, the net effect will depend on the system under investigation\(^{[18]}\). This suggestion, however, does not explain our observations of hyperglycaemia in response to low and hypoglycaemia to high doses and lack of effect to the highest dose tested of ketamine. Thus, we suggest that ketamine may possibly act on two sites with different activation thresholds and mediate opposite effects. Depending on the dose of the drug and the sensitivity of the site, ketamine can produce either hyper or hypoglycaemia, but at a certain dose level of ketamine both sites become operant and a state of balance is achieved with the net result no alteration of blood glucose level. It seems rather difficult to pinpoint with certainty the exact sites at which ketamine either directly or indirectly act to produce changes in blood glucose levels of conscious fasted rabbits.

As analgesic ketamine has been reported to act as an agonist at opiate receptors\(^{[19]}\). It has also been suggested that ketamine along with phencyclidine binds to, at least, two distinct sites, sigma opiate sites that mediate naloxone-insensitive psychomimetic effects of certain opioids and (phencyclidine) PCP-prefering site that is located within N-Methyl-D-Aspartate (NMDA) receptor ion channel and appears to inhibit the flux of cations, particularly Ca\(^{2+}\), that is initiated by glutamate and/or aspartate\(^{[20]}\). Ketamine has also been shown to have both inhibitory and excitatory effects on the peripheral nervous system\(^{[18,21]}\). More recently\(^{[16]}\), claimed that acute hyperglycaemia induced by a mixture of ketamine and xylazine is mediated by modulation of the glucoregulatory hormones through stimulation of \(\alpha_2\)-adrenoceptors.

In the present study, we subjected both the hyper- and hypo-glycaemic effects of ketamine to analysis using the opioid antagonist naloxone. In agreement with others\(^{[22,23]}\), we also observed that naloxone produced a functional synergism. This is further substantiated by the observation that the same dose of naloxone while loosing it’s effect, it completely abolished hypoglycaemia in response to i.v. ketamine (2 mg kg\(^{-1}\)). Moreover, hyperglycaemia in response to naloxone (1 mg kg\(^{-1}\), i.v.) was markedly potentiated in the presence of the highest dose of ketamine tested that was without any effect of it’s own on blood glucose levels. Since, hyperglycaemia in response to intravenous ketamine is not blocked by a non-hyperglycaemic dose of naloxone and since combination of hyperglycaemic doses of both drugs is synergistic, it seems possible that ketamine might be acting on either non-opioid, possibly PCP/NMDA or adrenergic receptors, to produce hyperglycaemia or it acts on a sub-population of opioid receptors that are resistant to naloxone, like \(\sigma\)-site mediating naloxone-insensitive effects\(^{[24]}\).

The possibility that ketamine-induced hyperglycaemia may be mediated via activation of \(\alpha_2\)-adrenoceptors has to be considered. It is well established that catecholamines can produce hyperglycaemia in rabbits\(^{[25-27]}\). Like adrenaline and noradrenaline, the selective \(\alpha_1\)-agonist phenylephrine\(^{[27]}\) and the selective \(\alpha_2\) agonist clonidine\(^{[28-30]}\) have both been shown to produce hyperglycaemia. and hyperglycaemia in response to ketamine/xylazine mixture has been inhibited in a dose-dependent manner by the selective \(\alpha_2\)-adrenoceptor antagonist yohimbine\(^{[16]}\). It has been suggested that in ketamine anaesthetized rats, both the inhibitory tone on insulin secretion and the glycogenolytic response are probably mediated by adrenergic innervation of the pancreas, liver and circulating catecholamines secreted from the adrenal medulla\(^{[31]}\). In the present study, the possible involvement of \(\alpha_1\)-adrenoceptors in mediating ketamine hyperglycaemia was explored by testing the effect of the latter drug in presence of the selective \(\alpha_1\)-antagonist WB-4101. Blockade of \(\alpha_1\)-adrenoceptors neither induced hyperglycaemia nor influenced that in response to ketamine. In addition, WB-4101 was also without effect on ketamine-induced hypoglycaemia. The failure of WB-4101 to block ketamine-induced hyperglycaemia recalls similar observation on failure of
prazocin to antagonize hyperglycaemia in response to adrenaline in both mice and rabbits\(^{32,34}\). In addition, hyperglycaemia-induced by phenylephrine was only partially attenuated by prazocin\(^{25}\). It has also been reported that in rabbits, β-adrenoceptor blockade with propranolol failed to antagonize the increase in blood glucose caused by either adrenaline or noradrenaline\(^{25,26}\). Hyperglycaemia in response to adrenergic agonists have been claimed to involve the stimulation of α\(_2\)-adrenoceptors\(^{29,32,33,35,36}\). It has also been shown that the selective α\(_2\)-adrenoceptor agonist UK14304 increases blood glucose levels in conscious fasted rabbits when infused alone\(^{37}\). However, the effect was antagonized in rabbits previously treated with the α\(_2\)-adrenoceptor antagonist 2-methoxyidazoxan\(^{37}\). Moreover, efaroxan, the α\(_2\)-adrenoceptor antagonist, when given alone it had a little effect on blood glucose level but it markedly antagonized the hyperglycaemic actions of UK14304 and adrenaline. These results provided a further support for the involvement of α\(_2\)-adrenoceptors in glucose homeostasis\(^{38}\). In our experiments both the hyper- and hypoglycaemic effects of ketamine were resistant to blockade of α\(_1\)-adrenoceptors with WB-4101. On the other hand, hyperglycaemia in response to i.v. ketamine was highly sensitive to yohimbine. These results clearly indicate that α\(_2\)-adrenoceptors significantly contribute to the hyperglycaemic response to ketamine. Surprisingly, when we tested ketamine-induced hypoglycaemia in the presence of yohimbine, it was reversed into hyperglycaemia. This later effect was resistant to α\(_1\)-adrenoceptor blockade with WB-4101, but highly sensitive to β-adrenoceptor blockade with propranolol. Taken together, the results may suggest that ketamine acts on α\(_2\)-adrenoceptors to produce hypoglycaemia and blockade of such receptors, unmasks an effect on β-adrenoceptor leading to hyperglycaemia. Our results indicate that hyperglycaemia in response to ketamine may be mediated mainly via α\(_2\)-adrenoceptors with opioid mechanisms playing only a minor role as the response was highly sensitive to blockade by yohimbine, but only partially reduced by naloxone. On the other hand, hypoglycaemia in response to ketamine may be mediated by an action on sites that are sensitive to both naloxone and yohimbine. Our observation that blockade of α\(_2\)-adrenoceptors with yohimbine reverses the hypoglycaemia induced by ketamine into hyperglycaemia that is sensitive to propranolol may suggest that β-adrenoceptors becomes operant and their activation by ketamine would lead to hyperglycaemia, only after inactivation of α\(_2\)-adrenoceptors. This view does not, however exclude a direct effect of ketamine on both α\(_2\) and β-adrenoceptors. Indeed, it has been suggested that the use of yohimbine to assess the role of α\(_2\)-adrenoceptors at any of these sites in the intact animal requires care that the observed responses are solely due to blockade of α\(_2\)-adrenoceptors and not to β-adrenergic effects of increased circulating catecholamines\(^{39}\). It seems possible that hyperglycaemia in response to ketamine may be mediated mainly through activation of α\(_2\)-adrenoceptors with opioid mechanisms playing only a minor role as the response was highly sensitive to blockade by yohimbine, but only partially reduced by naloxone. On the other hand, hypoglycaemia in response to ketamine may be mediated by an action on sites that are sensitive to both naloxone and yohimbine.

**CONCLUSION**

In summary, the present results clearly show a dose-dependent effect of ketamine on blood glucose levels in conscious rabbits. Low dose produces hyperglycaemia that is mediated via α\(_2\)-adrenoceptors while high doses produce hypoglycaemia mediated through opioid receptors with some involvement of β-adrenoceptors that becomes evident only after blockade of α\(_2\)-adrenoceptors.

**ACKNOWLEDGMENT**

This study is dedicated to the memory of the late Dr. A.K. Roychoudhury We are grateful to Mr. M. Mosa for his technical assistance, Mr. A. Subaih and Mr. E. Mohamed who were responsible for the care of the animals.

**REFERENCES**


